Abstract:Abstract While a number of low-frequency genetic variants of large effect size have been shown to underlie both cardiovascular disease and dementia, recent studies have highlighted the importance of common genetic variants of small effect size, which, in aggregate, are embodied by a polygenic risk score. We investigate the effect of polygenic risk for coronary artery disease on brain atrophy in Alzheimer’s disease using whole-brain volume and put our findings in context with the polygenic risk for Alzheimer’s disease and presumed small vessel disease as quantified by white-matter hyperintensities. We use 730 subjects from the Alzheimer’s disease neuroimaging initiative database to investigate polygenic risk score effects (beyond APOE) on whole-brain volumes, total and regional white-matter hyperintensities and amyloid beta across diagnostic groups. In a subset of these subjects (N = 602), we utilized longitudinal changes in whole-brain volume over 24 months using the boundary shift integral approach. Linear regression and linear mixed-effects models were used to investigate the effect of white-matter hyperintensities at baseline as well as Alzheimer’s disease-polygenic risk score and coronary artery disease-polygenic risk score on whole-brain atrophy and whole-brain atrophy acceleration, respectively. All genetic associations were examined under the oligogenic (P = 1e-5) and the more variant-inclusive polygenic (P = 0.5) scenarios. Results suggest no evidence for a link between the polygenic risk score and markers of Alzheimer’s disease pathology at baseline (when stratified by diagnostic group). However, both Alzheimer’s disease-polygenic risk score and coronary artery disease-polygenic risk score were associated with longitudinal decline in whole-brain volume (Alzheimer’s disease-polygenic risk score t = 3.3, PFDR = 0.007 over 24 months in healthy controls) and surprisingly, under certain conditions, whole-brain volume atrophy is statistically more correlated with cardiac polygenic risk score than Alzheimer’s disease-polygenic risk score (coronary artery disease-polygenic risk score t = 2.1, PFDR = 0.04 over 24 months in the mild cognitive impairment group). Further, in our regional analysis of white-matter hyperintensities, Alzheimer’s disease-polygenic risk score beyond APOE is predictive of white-matter volume in the occipital lobe in Alzheimer’s disease subjects in the polygenic regime. Finally, the rate of change of brain volume (or atrophy acceleration) may be sensitive to Alzheimer’s disease-polygenic risk beyond APOE in healthy individuals (t = 2, P = 0.04). For subjects with mild cognitive impairment, beyond APOE, a more inclusive polygenic risk score including more variants, shows coronary artery disease-polygenic risk score to be more predictive of whole-brain volume atrophy, than an oligogenic approach including fewer larger effect size variants.

Polygenic hazard score modified the relationship between hippocampal subfield atrophy and episodic memory in older adults

Correlation of hippocampal volume and cognitive performances in patients with either mild cognitive impairment or Alzheimer's disease.

Genetic Variants of PICALM Rs541458 Modulate Brain Spontaneous Activity in Older Adults with Amnestic Mild Cognitive Impairment

Polygenic Hazard Score Associated Multimodal Brain Networks along the Alzheimer's Disease Continuum.

Associations Between Alzheimer's Disease Polygenic Risk Scores and Hippocampal Subfield Volumes in 17,161 UK Biobank Participants.

Combining Polygenic Hazard Score With Volumetric MRI and Cognitive Measures Improves Prediction of Progression From Mild Cognitive Impairment to Alzheimer's Disease

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

Polygenic Risk for Alzheimer's Disease Influences Precuneal Volume in Two Independent General Populations

Endocytosis-pathway polygenic scores affects the hippocampal network connectivity and individualized identification across the high-risk of Alzheimer’s disease

Age-related polygenic effects of Alzheimer's disease on brain structures and cognition in middle aged and elderly adults from UK Biobank

Impact of PICALM and CLU on hippocampal degeneration

Genome-wide Association Study of Hippocampal Atrophy Rate in Non-Demented Elders

Polygenic hazard score predicts synaptic and axonal degeneration and cognitive decline in Alzheimer's disease continuum

Polygenic coronary artery disease association with brain atrophy in the cognitively impaired

The polygenic hazard score mediates the association between plasma neurofilament light chain and brain morphometry in dementia spectrum

ENDOCYTOSIS MULTILOCUS GENETIC PROFILE AFFECTS HIPPOCAMPAL NETWORK CONNECTIVITY AND INDIVIDUALIZES IDENTIFICATION ACROSS THE PRODROMAL STAGES OF ALZHEIMER’S DISEASE

Association of hippocampal volume polygenic predictor score with baseline and change in brain volumes and cognition among cognitively healthy older adults

Genetic risk score for Alzheimer's disease predicts brain volume differences in mid and late life in UK biobank participants

Atrophy of hippocampal subfields relates to memory decline during the pathological progression of Alzheimer's disease

Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer's Disease: a cross-sectional study

Impacts of CD33 Genetic Variations on the Atrophy Rates of Hippocampus and Parahippocampal Gyrus in Normal Aging and Mild Cognitive Impairment